to evaluate the efficacy of amphotericin B injection in trearment of cutaneous leishmaniasis.

Efficacy of intralesional amphotericin B for treatment of cutaneous leishmaniasis in patient referred to Dermatology Clinic of Imam Reza Hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201105223862N7

Enrollment

Registered

2011-11-20

Start date

2008-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Leishmaniasis. Cutaneous Leishmaniasis

Interventions

intralesional injection of Amphotricin, once weekly for 6-12 week..

Treatment - Other

intralesional injection of Amphotricin, once weekly for 6-12 week.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: diagnosis of Cl based on direct skin smear or biopsy, lesion number less than 4, hypersensitivity to Antimoniate, resistance to Antimoniate therapy, informed consent signing Exclusion criteria: hypersensitivity to amphotricin

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Lesion healing. Timepoint: weekly. Method of measurement: measuring the size of induration and ulcer by caliper.	—

Secondary

Measure	Time frame
Side effect. Timepoint: weekly. Method of measurement: clinical evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Vahid Mashayekhi

Research center for skin diseases and cutaneous leishmaniasis

mashayekhiv@mums.ac.ir+98 51 1802 2490

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026